1996 Volume 10 Issue 1 Pages 56-60
We describe herein the case of an 8-year-old girl with CMMoL. Previously, she was treated with etoposide and prednisolone, but she did not improve. Thus, we tried to administrate cytarabine ocfosfate (SPAC) as a treatment. Three courses of oral administration of SPAC (50 mg/day) for 2 weeks was given, and 100 mg/day for 2 weeks was repeated for two courses. During these treatments, thrombocytopenia improved without any adverse effects. So, she has been able to go to school and this treatment has resulted in an apparent improvement of QOL. However, there was no improvement on bone marrow and the treatment was discontinued for 7 months. She died of acute respiratory failure 6 months after the termination of treatment. We consider that the QOL of a patient is very important, especially in diseases with a poor prognosis. We recommend that SPAC is an effective treatment for MDS patients who can not receive bone marrow transplantation.
